NIOSHTIC-2 Publications Search
Dr R Shiffmann's Asthmador: relevant to our times, or a snake oil remedy?
Fedan JS; Piedimonte G
Curr Opin Pharmacol 2010 Jun; 10(3):213-217
We really would have liked to have been able to title this issue: 'Cures for Respiratory Diseases Found!' But we and you reading this issue at the time of its publication realize that this claim cannot be made. Alas, lung researchers have amassed a gargantuan level of knowledge about the diseases that are discussed in this issue: how patients present; the several morphological and pathophysiological changes that occur as the disease begins and progresses; some genetic, possibly etiologic, predispositions; and the mechanisms of action of most of the drugs that are used to prevent and/or ameliorate patient symptoms. Not that the 'cure' for these diseases lies ultimately in pharmacotherapy. At the outset we decided to limit the areas covered by this issue to asthma and cystic fibrosis. This was not done to slight other diseases such as tuberculosis, pneumonia, sarcoidosis and the many others, but because of the limitations of space.
Respiratory-system-disorders; Pulmonary-system-disorders; Lung-disease; Lung-disorders; Lung; Bronchial-asthma; Fibrosis; Fibrogenesis; Fibrogenicity
Jeffrey S Fedan, Pathology and Physiology Research Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA
Issue of Publication
Current Opinion in Pharmacology
Page last reviewed: December 17, 2021Content source: National Institute for Occupational Safety and Health Education and Information Division